(Q34376294)

1 August 2017

1 reference

title

Recent developments in adjuvants for vaccines against infectious diseases (English)

1 reference

1 August 2017

1 reference

O'Hagan DT

1

1 reference

1 August 2017

MacKichan ML

series ordinal

2

1 reference

1 August 2017

Singh M

series ordinal

3

1 reference

1 August 2017

publication date

1 October 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

18

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

69-85

1 reference

DNA vaccines--designer vaccines for the 21st century

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cationic microparticles: A potent delivery system for DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Detoxification of endotoxin by aluminum hydroxide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

1 reference

7 January 2021

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Introduction: the role of innate immunity in the adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Toll-like receptors in the induction of the innate immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Natural adjuvants: endogenous activators of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Innate immunity: the virtues of a nonclonal system of recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Tolerance, danger, and the extended family

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

An innate sense of danger

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Seeking wisdom in innate immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The instructive role of innate immunity in the acquired immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The role of dendritic cells in the induction and regulation of immunity to microbial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Dendritic cell survival and maturation are regulated by different signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Innate immune recognition and control of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Self-defense: the fruit fly style

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Endotoxin signal transduction in macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Human TH1 and TH2 subsets: doubt no more

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

T cells and dendritic cells get intimate

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

CpG motifs as immune adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The role of CpG motifs in innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Action of Saponin on Biological Cell Membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Dendritic cells internalize vaccine adjuvant after intramuscular injection

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Targeting immune response induction with cochleate and liposome-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

ISCOMs and other saponin based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immune responses to ISCOM formulations in animal and primate models

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Lipopeptide particles as the immunologically active component of CTL inducing vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Biodegradable microspheres in drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Improving protein therapeutics with sustained-release formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Controlled release microparticles for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Development of adjuvant-active nonionic block copolymers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A protein particle vaccine containing multiple malaria epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Optimism over vaccines administered via mucosal surfaces.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Protection against vaginal SIV transmission with microencapsulated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Biologically erodable microspheres as potential oral drug delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Microparticles and polymers for the mucosal delivery of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Production of hepatitis B surface antigen in transgenic plants for oral immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

A novel bioadhesive intranasal delivery system for inactivated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

T lymphocyte costimulation mediated by reorganization of membrane microdomains

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Skin immunization made possible by cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Transcutaneous immunization: a human vaccine delivery strategy using a patch

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The identification of plant lectins with mucosal adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Lectin-bearing polymerized liposomes as potential oral vaccine carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900101-0

7 January 2021

10.1016/S1389-0344(01)00101-0

Identifiers

DOI

1 reference

1 August 2017

1 reference